Biocon India Pvt. Ltd. is incorporated as a joint venture between Kiran Mazumdar-Shaw and Biocon Biochemicals Ltd. Ireland. Starting with three employees in a rented shed in Koramangala, suburban Bangalore. Biocon began manufacturing and exporting Papain, a plant enzyme, and Isinglass, a marine hydrocolloid – both, key products for the brewing industry.
Biocon’s first export was Papain, a plant enzyme derived from Papaya, to U.S. and Europe, signalling the company's ambition to produce high quality, world class products in India for global markets.
Biocon acquires a 20-acre plot on Hosur Road, Bangalore for INR 600,000 to expand operations. On March 8th, 1980, the foundation stone was laid for the building that currently houses the company’s corporate office.
Biocon decides to move beyond its frugal operations in rented premises and starts building its own integrated campus at 20th KM, Hosur Road, Electronics City, Bangalore.
Biocon’s new campus at 20th KM, Hosur Road, Electronics City, Bangalore is inaugurated by Irish Ambassador H.E. Bernard McHugh. Manufacturing activity shifted from the rented shed to the new site. R&D was also initiated.
Biocon established its R&D division, which initially focused on the development of solid state fermentation technology to develop novel enzymes.
Biocon Biochemicals Ltd, Ireland, including its subsidiaries, are acquired by Unilever Plc. and merged with its wholly-owned subsidiary Quest International, The Netherlands.
Biocon India begins producing enzymes for Unilever’s food businesses.
Biocon scales up its in-house research program based on a proprietary solid state fermentation technology through a new subsidiary Biochemizyme Ltd to scale up from pilot to plant level.
Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany, making it the first life sciences company in India to get the ISO 9001 Certification.
Syngene is incorporated as a Custom Research Organisation (CRO) in 1994 to provide efficient, high-quality, cost-effective research & development services in chemistry and biology to the global pharmaceutical industry.
Unilever acquires 50% stake in Biochemizyme and creates Biocon Quest India Ltd (BQIL), with Biocon and Unilever holding 50% stake each in the entity. A four-fold expansion of Biochemizyme’s solid state fermentation capacity aims to produce a range of fungal enzymes for the food and pharmaceutical industry.
Kiran Mazumdar-Shaw and John Shaw buy out Unilever’s share in Biocon India Ltd. making it an independent, privately owned company
Nobel Laureate Prof. James D. Watson, remembered for co-discovering DNA’s double-helix structure, visits Biocon.
Biocon establishes Clinigene as India's first Clinical Research Organisation to develop world-class capabilities for clinical research and related activities. Clinigene, a 100% subsidiary of Biocon, starts providing clinical research services to domestic and multinational companies.
PlaFractor, Biocon’s patented fermentation reactor, is commissioned. The indigenous PlaFractor fermentation platform proved a commercial success as Biocon was the first company to make Mycophenolate Mofetil using this technology in 2000.
Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals
Biocon is the first company globally to get U.S. FDA approval for making Lovastatin API through an innovative solid state fermentation technology.
Biocon’s proprietary bioreactor PlaFractor is granted a U.S. and worldwide patent.
Biocon establishes a joint venture company, Biocon Biopharmaceuticals Pvt Ltd, with CIMAB S.A., a Cuban biotechnology company, to manufacture biologicals developed by CIMAB, including Nimotizumab & Itolizumab monoclonal antibodies.
Biocon is the first company in the world to commercialise recombinant human insulin (rh-insulin), Insugen®, using a novel Pichia pastoris yeast expression system. Today, Biocon’s rh-insulin is approved in over 40 countries.
Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. The IPO received bids thirty-three times the 1 crore shares available for subscription during the bidding process. On Day 1 of listing on the bourses, Biocon closes with a market value of USD 1.1 billion, making Biocon only the second Indian company to cross the USD1 billion mark on the first day of listing.
Former President of India, Dr APJ Abdul Kalam, inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres.
External Link to Address by Dr APJ Abdul Kalam during Inauguration of Biocon Park
Biocon earns the distinction of being the first company in India to launch a novel biologic, Nimotuzumab, for head and neck cancer patients. Through the introduction of this molecule as BIOMAb EGFR®, Biocon enhanced the treatment outcome as well as quality of life of cancer patients in India.
Biocon Biopharmaceuticals, India's largest, state-of-the-art multi-product Biologics facility, inaugurated at Biocon Park for manufacturing a range of products encompassing monoclonal antibodies and other recombinant therapeutics. P. Chidambaram, former Union Minister of Finance, inaugurated the facility on April 17, 2006.
Biocon divests its legacy enzymes business to Novozymes for USD 115 million to increase focus on developing, manufacturing biopharmaceuticals.
Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH, for a consideration of EUR30 million to market and distribute a range of biopharmaceuticals in Germany and the rest of Europe. Biocon divested its stake in AxiCorp in 2011.
Biocon partners with U.S.-based Mylan for the co-development of a high-value portfolio of biosimilars for oncology and autoimmune indications. The portfolio initially included three monoclonal antibodies — Trastuzumab, Bevacizumab and Adalimumab — and two recombinant proteins — Pegfilgrastim and Etanercept. It marked one of the earliest partnerships in the global biosimilars space.
Biocon launched Insulin Glargine under the brand name Basalog® in India, providing diabetes patients with an advanced, affordable insulin therapy.
Syngene inaugurates a fully dedicated research and development facility for Bristol-Myers Squibb at Biocon Park.
Biocon and Pfizer enter into a strategic global agreement for the worldwide commercialisation of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Biocon and Pfizer amicably dissolved their global partnership in 2012 and all rights licensed to Pfizer for these insulin molecules reverted to Biocon.
Biocon announces the project commencement of its state-of-the-art insulin manufacturing and R&D facility, the largest integrated insulin facility in Asia, at Bio-XCell in Johor, Malaysia.
Biocon launched in India its world-class, reusable insulin delivery device INSUPen® designed for efficiently, accurately and safely delivering both Basalog and Insugen, thus maximising patient convenience.
Biocon inaugurated a state-of-the-art Biocon Research Centre, spread across 200,000 sq ft, as part of its aspiration to build a centre of research excellence to accelerate a culture of innovation to promote path breaking research for biopharmaceuticals.
Biocon launched Itolizumab, a novel, first-in-class humanised anti-CD6 monoclonal antibody approved for treating psoriasis, under the brand name ALZUMAb™ in India. This is the ﬁrst anti-CD6 monoclonal antibody in the world to be commercialised, which makes it a path breaking innovation to come out of an Indian laboratory.
Biocon House, which now houses Biocon Biologics India Ltd, is inaugurated at Semicon Park, Electronic City, Bangalore
Biocon establishes Biocon Academy as a Centre of Excellence for Advanced Learning in Applied Biosciences under its Corporate Social Responsibility (CSR) agenda as part of the company’s commitment to create a globally competitive biotech ecosystem in India through skill development.
Biocon introduces CANMAb™ in India as the world’s lowest priced Trastuzumab, opening the doors for HER2-positive metastatic breast cancer patients to access an affordable therapy.
Biocon’s research services subsidiary, Syngene, debuts on the Indian stock market. Syngene’s market capitalisation crossed USD 1 billion within a week of listing.
Biocon inaugurates a state-of-the-art 100,000 square feet facility in Bangalore for manufacturing new generation, patient-friendly devices for its insulins portfolio.
Biocon also launches Basalog One, a high-end, pre-filled Insulin Glargine pen that is almost painless, safe and convenient to administer.
Biocon receives European approval for its generic Rosuvastatin Calcium tablets. This is Biocon's first Generic Formulations approval in the regulated markets and marks an important milestone in the company’s forward integration from generic APIs to generic finished dosages.
Biocon achieves a major regulatory milestone when Japan's health regulator approves the sale of its biosimilar Insulin Glargine, partnered locally with FUJIFILM Toyama Chemical. This is Biocon’s first biosimilar approval in a developed market and the first biosimilar from a company in India to be approved in Japan.
Biocon and Mylan create history by becoming the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) is the first biosimilar from Biocon and Mylan’s joint portfolio approved in the U.S. and Biocon is the first Indian company to receive a U.S. FDA approval for a biosimilar.
Biocon starts commercial operations at its first overseas insulins manufacturing facility in Malaysia. Biocon’s rh-Insulin is the first locally manufactured biosimilar product to be approved for sale by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.
Biocon licensed Itolizumab for the U.S. and Canada markets to San Diego-based biotechnology company Equillium through an equity stake. Later, it expanded the scope of the licensing agreement with Equillium for Itolizumab, to include Australia and New Zealand.
Biocon successfully launches its biosimilar Bevacizumab in India as KRABEVA® for patients of various types of cancer. KRABEVA®, the second oncology biosimilar launched in India after CANMAb (Trastuzumab), is prescribed for metastatic colorectal cancer (mCRC) and several other types of lung, kidney, cervical, ovarian and brain cancers.
Biocon achieves another milestone with the approval and launch in the U.S. of Fulphila™, biosimilar Pegfilgrastim co-developed with partner Mylan. Biocon is the first company from India to have a biosimilar commercialised in the U.S.
Biocon and Mylan’s biosimilar Insulin Glargine, Semglee, receives European approval for commercialisation.
Biocon enters into a global partnership with Sandoz, a Novartis division and a global player in biosimilars to develop a next-generation biosimilars portfolio, which will help patients worldwide gain access to a range of high quality, affordable immunology and oncology biologics.
Fulphila®, a biosimilar Pegfilgrastim jointly developed by Biocon and Mylan, is granted Marketing authorisation by the European Commission. Ogivri®, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, also gets EC’s nod.
Biocon consolidates the development, manufacturing and commercialisation operations of its biosimilars business under an independent entity, Biocon Biologics, with its own dedicated management.
Biocon becomes the first Indian player to launch biosimilar Trastuzumab, Ogivri, in the U.S. through partner Mylan.
Bicara Therapeutics is incorporated as a wholly owned subsidiary of Biocon in Boston, U.S., to focus on developing a pipeline of bi-functional antibodies that exploit the advances in immuno-oncology.
Biocon Biologics approves a primary equity investment by True North, starting the value unlocking process for Biocon's biosimilars subsidiary.
The Drugs Controller General of India (DCGI) approves 'restricted emergency use' of Itolizumab (ALZUMAb®) in India, a repurposed drug, for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.
Tata Capital Growth Fund makes a primary equity investment for a minority stake in Biocon Biologics.
Biocon and Mylan achieve the key milestone of receiving U.S. FDA approval and bringing to market both the vial and pen presentations of Semglee (insulin glargine injection), the first for any company following the reference product.
Transaction Values Biocon Biologics at USD 3.94 Billion